2019-004375-40: Study for the evaluatiion of Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“PRO-SID” study) Studie zur Ermittlung der Wirksamkeit und Sicherheit von Panzyga in der primären Infektionsprophylaxe bei Patienten mit chronischer lymphatischer Leukämie ("PRO-SID"-Studie) |
|
|
| Not yet recruiting | 3 | 450 | Europe, RoW | Panzyga, [NA], Solution for infusion, Panzyga | Octapharma Pharmazeutika Produktionsges.m.b.H., OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H., Octapharma Pharmazeutika Produktionsges.m.b.H. | Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia, Prophylaxis to prevent infection in patients with a type of cancer that starts in bone marrow and then go into the blood, Diseases [C] - Cancer [C04] | | | | |
PROSID, NCT04502030: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) |
|
|
| Recruiting | 3 | 240 | Europe, US, RoW | Panzyga, Placebo | Octapharma | Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | 10/25 | 10/25 | | |